Determining procalcitonin at point-of-care; A method comparison study of four commercial PCT assays

Li, Chunbao; Huang, Ya‐Ping; Xu, Yong

doi:10.1016/j.plabm.2021.e00214

Cited by 6 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LIP tool was developed based on the pathophysiological nature of sepsis-induced immunosuppression, procoagulant dysfunction, and the systemic inflammatory response, and the three biomarkers included in the LIP scoring system can be routinely assessed at most medical institutions worldwide. Many medical institutions can also carry out point-of-care testing (POCT), which greatly shortens the screening time for sepsis [19][20][21][22] . The combination of multiple biomarkers has complementary advantages, and ROC analysis showed that the LIP scoring tool has satisfactory screening efficacy.…”

Section: Discussionmentioning

confidence: 99%

Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)

Liu

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Exploring an effective sepsis screening tool that can be widely implemented is important for improving the prognosis of sepsis worldwide. This study aimed to develop a new simple screening tool for sepsis (LIP scoring system) that includes the peripheral blood lymphocyte count, international normalized ratio, and procalcitonin level. In a single-center, prospective, observational study, 444 acute sepsis inpatients and 444 nonsepsis inpatients were ultimately included based on the Sepsis-3 and exclusion criteria. The differences in the Lym, INR, PCT level and other clinical biomarkers were compared between the two groups. Univariable and multivariable logistic regression analyses and receiver operating characteristic analysis were used to establish a LIP screening tool for sepsis with a combination of biomarkers. The Kappa and McNemar tests were used to evaluate the differences between the LIP screening results (LIP score ≥ 3) and Sepsis-3 criteria (SOFA score ≥ 2). Logistic regression analysis showed that the lymphocyte count, INR, PCT level, platelets, neutrophil/lymphocyte ratio (NLR) and prothrombin time (PT) were independent risk factors for the development of sepsis. The ROC analysis showed that the lymphocyte count, INR, and PCT level had high area under the ROC curve values (AUROC (95% CI): Lym 0.84 (0.810–0.860), INR 0.921 (0.902–0.938), PCT level 0.928 (0.909–0.944)). The LIP tool had satisfactory screening efficacy for sepsis (sensitivity, 92.8%; specificity, 94.1%), and a LIP score equal to or greater than 3 points had good agreement with Sepsis-3 criteria in the diagnosis of sepsis (Kappa = 0862 in the Kappa test and P = 0.512 in the McNemar test). The LIP tool has satisfactory sensitivity and specificity for sepsis screening, and it can be used for rapid screening of patients with sepsis in outpatient and emergency departments or in economically underdeveloped areas with limited resources.

show abstract

Section: Discussionmentioning

confidence: 99%

Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)

Liu

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…There are other, less commonly used techniques, such as immunoturbidimetric assay. [ 57 ] [ 60 ] [ 61 ] [ 62 ] Ferritin IFA Immunoturbidimetric, LAA, ELISA, RIA, IRMA Among the POC devices is the ichroma II [ 57 ] [ 63 ] [ 64 ] Hematological Lymphocyte Automatic hematological analyzer Automatic hematological analyzer, flow cytometer and Coulter counting The NLR is calculated as the ratio of the absolute neutrophil count to the absolute lymphocyte count. Hematological analyzers such as the HemoCue WBC DIFF system are available for POC detection.…”

Section: Covid-19 Biomarkers: From Diagnosis To Prognosis and Predict...mentioning

confidence: 99%

Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine

Vásquez

Orozco

2022

Anal Bioanal Chem

View full text Add to dashboard Cite

As a more efficient and effective way to address disease diagnosis and intervention, cutting-edge technologies, devices, therapeutic approaches, and practices have emerged within the personalized medicine concept depending on the particular patient's biology and the molecular basis of the disease. Personalized medicine is expected to play a pivotal role in assessing disease risk or predicting response to treatment, understanding a person's health status, and, therefore, health care decision-making. This work discusses electrochemical biosensors for monitoring multiparametric biomarkers at different molecular levels and their potential to elucidate the health status of an individual in a personalized manner. In particular, and as an illustration, we discuss several aspects of the infection produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a current health care concern worldwide. This includes SARS-CoV-2 structure, mechanism of infection, biomarkers, and electrochemical biosensors most commonly explored for diagnostics, prognostics, and potentially assessing the risk of complications in patients in the context of personalized medicine. Finally, some concluding remarks and perspectives hint at the use of electrochemical biosensors in the frame of other cutting-edge converging/emerging technologies toward the inauguration of a new paradigm of personalized medicine. Graphical abstract

show abstract

“…Examples of POC analyzers available in 2021 for PCT testing include the AQT90 FLEX (Radiometer, Copenhagen, Denmark), mLabs (Micropoint, Shenzhen, China), Finecare (Wondfo, Guangzhou, China), and Getein 1100 (Getein Biotech Inc., Nanjing, China) [ 6 ]. Studies indicate that the AQT90 FLEX PCT assay demonstrates good agreement and precision compared to the reference immunoassay [ 6 ]. A coefficient of variation (CV) of less than 5% was observed in both plasma and whole blood at 0.5 ng/mL and 2.0 ng/mL PCT levels [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Studies indicate that the AQT90 FLEX PCT assay demonstrates good agreement and precision compared to the reference immunoassay [ 6 ]. A coefficient of variation (CV) of less than 5% was observed in both plasma and whole blood at 0.5 ng/mL and 2.0 ng/mL PCT levels [ 6 ]. However, the assay stability is only up to 8 months and requires conditions of 2–8 degrees for storage of the reagent [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Analytical Evaluation of Point-of-Care Finecare™ Procalcitonin Rapid Quantitative Test in Sepsis Population as Compared with Elecsys® BRAHMS Procalcitonin Immunoassay

Mazlan,

Wan Azman,

Yaacob

et al. 2024

Diagnostics

View full text Add to dashboard Cite

The study compared two plasma procalcitonin (PCT) assays, the point of care (POC) Finecare™ Procalcitonin Rapid Quantitative Test and the Elecsys® BRAHMS PCT immunoassay, in sepsis ICU patients. Forty-one plasma samples were analyzed, showing a strong correlation (r = 0.98) and no significant difference in PCT values. The mean POC PCT value was 4.46 ng/mL (SD 8.68), and for laboratory BRAHMS PCT, it was 4.67 ng/mL (SD 10.03). The study found a strong linear relationship between plasma POC PCT and laboratory BRAHMS PCT (r = 0.98). Different regression methods showed varying intercepts and slopes: Ordinary Least Squares had an intercept of 0.49 and a slope of 0.85; Deming regression showed an intercept of 0.43 and a slope of 0.86; Passing–Bablok regression showed an intercept of 0.02 and a slope of 1.08. Precision results for cut-offs of 0.5 ng/mL were a coefficient of variation (CV) of 5%, and for 2.5 ng/mL, the CV was 2.5%. The Pearson correlation coefficient (r) for linearity was ≥0.99. The study revealed no significant difference between the POC Finecare™ PCT and Elecsys® BRAHMS PCT immunoassay in sepsis samples from ICU patients, supported by strong correlation, minimal bias, a consistent CV, and linearity.

show abstract

Determining procalcitonin at point-of-care; A method comparison study of four commercial PCT assays

Cited by 6 publications

References 16 publications

Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)

Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)

Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine

Analytical Evaluation of Point-of-Care Finecare™ Procalcitonin Rapid Quantitative Test in Sepsis Population as Compared with Elecsys® BRAHMS Procalcitonin Immunoassay

Contact Info

Product

Resources

About